Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

Waldo L L D Mattos,Nasreen Khalil,Lisa G Spencer,Francesco Bonella,Rodney J Folz,J Douglass Rolf,Nesrin Mogulkoc,Lisa H Lancaster,R Gisli Jenkins,David A Lynch,Paul W Noble,Toby M Maher,Vincent Cottin,Stefanie Senger,Gerald S Horan,Steven Greenberg,Zoran Popmihajlov,Waldo L. L. D. Mattos,Lisa G. Spencer,Rodney J. Folz,Lisa H. Lancaster,R. Gisli Jenkins,David A. Lynch,Gerald S. Horan

DOI: https://doi.org/10.1164/rccm.202310-1907oc

IF: 24.7

2024-03-14

American Journal of Respiratory and Critical Care Medicine

Abstract:<b>Rationale</b>: Idiopathic pulmonary fibrosis is a fatal and progressive disease with limited treatment options. <b>Objectives:</b> To assess the efficacy and safety of CC-90001, an oral inhibitor of c-Jun N-terminal kinase 1, in patients with idiopathic pulmonary fibrosis. <b>Methods:</b> NCT03142191 was a phase 2, randomized (1:1:1), double-blind, placebo-controlled study in which patients received CC-90001 (200 or 400 mg) or placebo once daily for 24 weeks. Background antifibrotic treatment (pirfenidone) was allowed. The primary endpoint was change in percentage of predicted forced vital capacity (ppFVC) from baseline to Week 24; secondary endpoints included safety. <b>Measurements and Main Results:</b> In total, 112 patients received ≥1 dose of study drug. The study was terminated early due to a strategic decision made by the sponsor. Ninety-one patients (81%) completed the study. The least-squares mean changes from baseline in ppFVC at Week 24 were -3.1% (placebo), -2.1% (200 mg), and -1.0% (400 mg); the differences compared with placebo were 1.1% (200 mg; 95% CI: -2.1, 4.3; <i>P</i>=.50) and 2.2% (400 mg; 95% CI: -1.1, 5.4; P=.19). Adverse event frequency was similar in patients in the combined CC-90001 arms versus placebo. The most common adverse events were nausea, diarrhea, and vomiting, which were more frequent in patients in CC-90001 arms versus placebo. Fewer patients in the CC-90001 than in the placebo arm experienced cough and dyspnea. <b>Conclusions:</b> Treatment with CC-90001 over 24 weeks led to numerical improvements in ppFVC in patients with idiopathic pulmonary fibrosis compared to placebo. CC-90001 was generally well tolerated, consistent with previous studies. Clinical trial registration available at www.clinicaltrials.gov, ID: NCT03142191.

respiratory system,critical care medicine